Head-to-head evidence
salbutamol vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
salbutamol
Developed by GlaxoSmithKline
NCT03528577 · Phase 3 · completed
The study randomized 128 participants in a quadruple-blind, four-period crossover design with active and placebo comparators. However, its primary endpoint was a pharmacodynamic surrogate rather than a hard clinical outcome. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Next expected readout: June 2027 · NCT06473779 (registry estimate)
Vilanterol
Marketed by GlaxoSmithKline
NCT01706198 · Phase 3 · completed
The study randomized 4,233 participants to FF/VI or active usual care, but neither participants nor investigators were blinded. Its primary patient-reported asthma-control endpoint was a surrogate/soft measure and was met in favor of FF/VI (71% vs 56%; p<0.001), supporting moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: salbutamol's landscape · Vilanterol's landscape